Fig. 1From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapyStudy design. *In the case of taking fibrate class drugs, at least two weeks of a wash-out period had taken during the screening period before starting the run-in periodBack to article page